Table 1.
Main characteristics of the studies included in the meta-analysis
| Author | Year | Country | Recruitment period | No. of patients | Age (years) | Gender (m/f) | Follow-up (months) | Survival analysis |
|---|---|---|---|---|---|---|---|---|
| Mayr et al. [12] | 2018 | Muti-centers | 2004–2014 | 500 |
Median (IQR) 72(65–78) |
401/99 |
Median (IQR) 35 (20–58) |
Age, gender, LNM, LVI, STSM, CIS, ACT |
| Hodgson et al. [13] | 2018 | Japan | 1999–2005 | 235 |
Mean (range) 70.1 (46–93) |
167/68 |
Median (range) 16 (1–206) |
LNM, LVI, STSM |
| Muppa et al. [14] | 2017 | USA | 1980–2010 | 965 |
Mean ± SD 67 ± 10.1 |
761/204 | Mean 127.2 | gender, LNM, LVI, STSM, histology, ACT |
| Li et al. [15] | 2017 | China | 2004–2015 | 1,676 |
Mean (range) 66.4 (24–92) |
1,376/300 |
Median (range) 78 (4–138) |
Age, gender, grade, LVI |
| Kang et al. [16] | 2017 | Korea | 1999–2012 | 385 |
Mean (range) 66 (59–72) |
333/52 | NA | Age, grade, stage, LNM, LVI, STSM,CIS |
| Gorgel et al. [17] | 2017 | Turkey | 2006–2016 | 149 |
Mean ± SD 61.6 ± 9.13 |
139/10 | NA | Age, gender, grade, stage, LNM, LVI |
| Andera et al. [18] | 2017 | USA | 1988–2003 | 448 |
Median (IQR) 65(60–71) |
373/75 |
Median (IQR) 170.4(122.4–205.2) |
Age, gender, LNM, LVI, histology, ACT |
| Crozier et al. [19] | 2017 | Australia | 2005–2014 | 220 |
Mean (range) 69.5 (60.3–74.9) |
177/43 | NA | gender, STSM |
| Morizawa et al. [20] | 2016 | Japan | 2002–2013 | 110 |
Median (IQR) 72(65–76) |
86/24 |
Median (IQR) 37.5 (11–65) |
LNM, stage, |
| Liu et al. [21] | 2016 | China | 2000–2013 | 296 |
Mean ± SD 61.7 ± 11.1 |
250/46 |
Median (IQR) 72.0 (49.0–121.0) |
Age, gender, grade, LNM, ACT |
| Bostrom et al. [22] | 2016 | Muti-centers | 1986–2008 | 581 | NA | 457/124 |
Median 68.4 |
Age, gender, grade, stage, LNM, ACT |
| Alimi et al. [23] | 2016 | France | 1992–2012 | 331 |
Mean ± SD 65.7 ± 11.4 |
272/59 |
Median (range) 52.6 (6–267) |
Age, LNM, LVI, ACT |
| Soave et al. [24] | 2015 | Germany | 1996–2011 | 517 |
Median (IQR) 67(59–73) |
400/117 |
Median (IQR) 45(21–83) |
Age, gender, grade, LNM, LVI, STSM, CIS, ACT |
| Raza et al. [25] | 2015 | Muti-centers | 2003–2015 | 702 |
Median (IQR) 69(61–76) |
569/133 |
Median (IQR) 67(8–84) |
Age, gender, stage, LNM, STSM, histology, ACT |
| Ozcan et al. [26] | 2015 | Turkey | 1990–2013 | 286 |
Mean ± SD 60.7 ± 19.42 |
256/30 |
Median (range) 8 (0–144) |
Age, gender, grade, stage, LNM, LVI, STSM, histology, CIS |
| Kwon et al. [27] | 2015 | Korea | 1990–2012 | 746 |
Mean ± SD 62.4 ± 9.7 |
664/82 |
Median (range) 64.3 (1–231.4) |
grade, stage, LNM, LVI, STSM, CIS |
| Kanatani et al. [8] | 2015 | Japan | 1990–2012 | 61 |
Median (IQR) 64(59–75) |
55/6 |
Median (IQR) 29(17–59) |
Age, gender, grade, stage, LNM, LVI, STSM, ACT |
| Ferro et al. [28] | 2015 | Italy | 2008–2013 | 1,037 |
Median (range) 70 (42–88) |
804/233 |
Median (range) 22 (3–60) |
Age, grade, CIS,ACT |
| Booth et al. [29] | 2015 | Canada | 1994–2008 | 2,944 |
Median 69 |
2,107/695 | NA | gender, stage, LNM, LVI, STSM, ACT |
| Albisinni et al. [30] | 2015 | Belgium | 2000–2013 | 503 |
Median (IQR) 68 (62–74) |
414/89 |
Median (IQR) 50(19–90) |
LNM, STSM |
| Kawai et al. [31] | 2014 | Japan | 1990–2005 | 84 |
Median (range) 65 (39–81) |
70/14 | NA | LNM, LVI |
| Kaushik et al. [32] | 2014 | USA | 1980–2005 | 128 |
Median (IQR) 72 (64–74) |
91/37 |
Median (IQR) 126(116.4–145.2) |
gender, LNM, STSM, ACT |
| Brunocilla et al. [33] | 2013 | Italy | 1995–2011 | 282 |
Median (IQR) 70 (63–75) |
234/48 |
Mean (range) 59.2 (1–171) |
Age, gender, grade, LNM, LVI, histology, ACT |
| Aziz et al. [3] | 2013 | Germany | 2004–2010 | 150 |
Median (IQR) 70 (64–76) |
121/29 |
Median (IQR) 46 (31–62) |
Age, gender, grade, stage, LNM, LVI, CIS,ACT |
| Otto et al. [34] | 2012 | Germany | 1989–2008 | 2,483 |
Median (IQR) 66.4(60.1–72.5) |
1,976/507 |
Median (IQR) 42(21–79) |
Age, grade, stage, LNM, LVI, CIS, ACT |
| Gondo et al. [35] | 2012 | Japan | 2008–2009 | 194 |
Mean (range) 68(38–85) |
162/32 |
Mean (range) 26.8 (3.1–131.8) |
gender, stage, LVI, STSM |
| Yafi et al. [36] | 2011 | Muti-centers | 1998–2008 | 2,287 |
Median (range) 68(26–90) |
1,803/484 |
Median (IQR) 29.3(9–50) |
Age, gender, grade, stage, LNM, STSM, histology, ACT |
| Faba et al. [37] | 2011 | Spain | 1978–2002 | 141 |
Median (range) 63 (47–80) |
116/25 |
Mean (range) 42.5 (1.3–246) |
LNM, LVI, CIS, ACT |
| Manoharan et al. [5] | 2010 | USA | 1992–2008 | 357 | NA | 185/72 | NA | LNM, LVI |
| Canter et al. [6] | 2009 | USA | 1988–2006 | 406 |
Mean ± SD 65.5 ± 10 |
NA |
Mean 46.4 |
Age, LNM |
| Muramaki et al. [38] | 2008 | Japan | 1995–2004 | 51 |
Median (range) 65 (46–74) |
43/8 |
Median (range) 26.5 (6–102) |
Age, gender, grade, LNM, LVI, CIS |
| Turkolmez et al. [39] | 2007 | Turkey | 1990–2005 | 225 | NA | NA | NA | Age, gender, LNM,,LVI |
| Karam et al. [40] | 2007 | USA | 1987–2002 | 222 |
Median (IQR) 66.2(58–74/7) |
177/45 |
Median (IQR) 36.9(13.3–79) |
grade, LNM, LVI, CIS, ACT |
m/f: male/femal; SD: standard deviation; NA, data not applicable; LNM: lymph node metastasis, LVI: lymphovascular invasion, STSM: soft tissue surgical margin, CIS: carcinoma in situ, ACT: adjuvant chemotherapy